Quick Answer
BridgeBio Pharma, Inc. reported Long Term Debt of $437.34 million for the year ending 2024.
- BridgeBio Pharma, Inc. showed a decrease of -2.0% in Long Term Debt from 2023 to 2024.
- This data is from BridgeBio Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on February 20, 2025.
- XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $75.02 million | Q1 2020: $92.42 million | Q2 2020: $92.91 million | Q3 2020: $93.39 million | Q1 2021: $90.76 million | Q2 2021: $102.61 million | Q3 2021: $103.14 million | Q1 2022: $434.11 million | Q1 2023: $435.76 million | Q2 2023: $440.50 million | Q3 2023: $441.72 million | Q1 2024: $434.72 million | Q2 2024: $435.45 million | Q3 2024: $436.22 million | Q4 2024: $437.34 million | Q1 2025: $0.00 | Q2 2025: $0.00.
- Over the full 7 years of available data (2018 to 2024), BridgeBio Pharma, Inc.'s Long Term Debt has grown by 702.4%.
- Historical annual values: Fiscal year 2024: $437.34 million | Fiscal year 2023: $446.45 million | Fiscal year 2022: $430.99 million | Fiscal year 2021: $430.75 million | Fiscal year 2020: $92.42 million | Fiscal year 2019: $91.79 million | Fiscal year 2018: $54.51 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: